Among adults aged 20–64, 91 percent had experienced tooth decay and 27 percent had untreated tooth decay. AI-driven dental imaging software can help make sense of the data quickly and efficiently. Normally it is the decay of the outer surface of a tooth as a result of bacterial action. "proper oral hygiene practices will go a long way in the prevention of tooth decay" AI-driven dental imaging software can help make sense of the data quickly and efficiently. AI can help out by providing additional detection tools and automated depth probing.

This edition of Digital Health News industry round-up includes projects focusing on artificial intelligence (AI), an app to tackle health inequalities and a project to use primary care data to help eradicate hepatitis C. The Royal Marsden NHS Foundation Trust and the Francis Crick Institute are working with AI start-up Owkin to gain a better understanding of how kidney cancers evolve to help improve treatment for the disease. By studying the evolutionary features of a tumour and understanding how it has evolved through a series of genetic changes over time, scientists hope to help doctors predict a patient's outcome, meaning they can tailor treatment to individuals to improve health outcomes. Dr Samra Turajlic, group leader at the Francis Crick Institute and consultant medical oncologist at The Royal Marsden NHS Foundation Trust, said: "We know that the outcomes of any individual patient with kidney cancer are determined by the distinct way their tumour evolves. We want to be able to predict the next step in a tumour's evolutionary trajectory and better tailor treatments that can effectively tackle a patient's cancer. "New technologies and tools are critical in helping us achieve this at a scale and speed that is required in clinical practice, and at a cost that will make these measurements implementable in most healthcare systems." It hopes that it will be able to draw links between the histological characteristics of a tumour with patient outcomes. This will also support the move to precision medicine. The project will use rapid and low-cost AI on digital pathology, helping the day-to-day management of patients in a cost-effective way. Thomas Clozel, co-founder and CEO of Owkin, said: "By using AI to improve our fundamental understanding of cancer tumours, we aim to enable doctors to move towards a precision medicine approach to treatment.